Your session is about to expire
← Back to Search
Behavioral Intervention
Potassium-Restricted Diet for Hyperkalemia (EvoKe-HD Trial)
N/A
Waitlist Available
Research Sponsored by Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Receiving hemodialysis 3 times/week for ≥ 3 months
≥18 years or older
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months
Awards & highlights
EvoKe-HD Trial Summary
This trial will assess a dietary approach to reducing high potassium levels in the body, including foods with high bioavailable potassium.
Who is the study for?
This trial is for adults who speak French or English, have had at least two high potassium blood tests in the last 3 months, and regularly attend hemodialysis sessions. It's not for those with limited control over their diet, a life expectancy under six months, or significant cognitive issues.Check my eligibility
What is being tested?
The EvoKe-HD study is testing a new dietary method to manage high potassium levels by limiting foods with easily absorbed potassium versus the traditional approach of avoiding high-potassium whole foods.See study design
What are the potential side effects?
Since this trial involves dietary changes rather than medication, side effects may include nutritional deficiencies or imbalances if not monitored properly.
EvoKe-HD Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I have been on hemodialysis 3 times a week for at least 3 months.
Select...
I am 18 years old or older.
Select...
I have missed no more than one dialysis session in the last 3 months.
EvoKe-HD Trial Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 6 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Change in average mid-week predialysis potassium level during the study period
Percentage of prevalent dialysis patients recruited and retained for 6 months
Secondary outcome measures
1-week average inter-dialytic weight gain (kg/day)
1-week average post dialysis blood pressure (mmHg)
1-week average pre dialysis blood pressure (mmHg)
+30 moreOther outcome measures
All-cause mortality
Major cardiovascular events
Standardised Outcomes in NephroloGy fatigue measure
EvoKe-HD Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: Restriction high bioavailability potassium sourcesExperimental Treatment1 Intervention
Participants will be asked to identify and avoid food items with potassium additives by revising the ingredient lists of the grocery products they consume. They will also be asked to reduce two sources of high bioavailability potassium, such as meat, milk, fruit juices, processed potatoes or coffee.
Group II: ControlActive Control1 Intervention
Participants will be asked to reduce the intake of food items with high total potassium content. A list of moderate-to-high potassium food items will be provided to the participants.
Find a Location
Who is running the clinical trial?
Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de MontrealLead Sponsor
12 Previous Clinical Trials
4,281 Total Patients Enrolled
Canadian Institutes of Health Research (CIHR)OTHER_GOV
1,341 Previous Clinical Trials
26,452,653 Total Patients Enrolled
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Is enrollment in this trial still open to new participants?
"Contrary to popular belief, this clinical trial is no longer actively seeking participants. Initially posted on January 1st 2024 and most recently updated on November 4th 2023, the study has since been closed off for recruitment. However, there are currently 20 other trials open for enrollment at this time."
Answered by AI
Share this study with friends
Copy Link
Messenger